Floatz logo
Floatz Rating
CCC54/100
Confidence
Indicative
v0.2
Sponsor
Shanghai Best-Link Bioscience, LLC
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07550842CT.gov
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
—Not Yet Recruiting———
NCT07414927CT.gov
A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
—Not Yet Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.

Same indication · Small Cell Lung Carcinoma

AssetSponsorPhaseRating
bl0020 (this asset)Shanghai Best-Link Bioscience, LLCP1/2CCC · 54
BenmelstobartYayi HeP4A
BerzosertibNational Cancer Institute (NCI)P2BBB
Anti-Pd-L1 Monoclonal Antibody Shr-1316Suzhou Suncadia Biopharmaceuticals Co., Ltd.P3BBB
Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)P4BBB
EtoposideSichuan UniversityP4BBB
VeliparibCentral European Society for Anticancer Drug ResearchP2BB
CarboplatinUniversity of Maryland, BaltimoreP4BB
L-Kappa-H-Gamma1 (Knob) Chain Anti-Dll3 (1-705) [L-Kappa Anti-Dll3 (1-214) [V-Kappa (Homo Sapiens Igkv1-17*03 (94.9%) -Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-Mer (Ggggse Gkssgsgses Kstegkssgs Gseskstggggs) Linker (215-252) -H-Gamma-1 Heavy Chain Anti-Dll3 (253-705) [Vh (Homo Sapiens Ighv1-46*01 (92.9%) -(Ighd) -Ighj6*01 (94.7%), Cdr-Imgt [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V32 Ch3 W22 (Knob) (Ch1 R120 (473) (377-474), Hinge 1-15 (475-489), Ch2 L1.3>A (493), L1.2>A (494) (490-599), Ch3 E12 (615), M14 (617), T22>W (625) (600-704), Chs K2>Del (705)) (377-705)]]; L-Lambda6-H-Gamma1 (Hole) Chain Anti-Cd3E (1-707) [L-Lambda6 Anti-Cd3 (1'-215') [V-Lambda Musmus/Homsap (Mus Musculus Iglv1*01 (82.3%) -Iglj1*01 (100%)/Homo Sapiens Iglv7-46*01 (76.8%) -Iglj3*02 (100%), Cdr-Imgt [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo Sapiens Iglc6*01 (100%) (110'-215')] -38-Mer (Ggggse Gkssgsgses Kstegkssgsgseskstggggs) Linker (216'-253') -H-Gamma-1 Anti-Cd3E (254'-707') [Vh Musmus/Homsap (Mus Musculus Ighv10-1*02 (92.9%) -(Ighd) -Ighj3*01 (100%)/Homo Sapiens Ighv3-73*01 (87.0%) -(Ighd) -Ighj6*01 (81.8%) T123>L (373'), S128>A (378'), Cdr-Imgt [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V33 Ch3 S22, A24, V86 (Hole), G1V83 Ch3 R115, F116 (Ch1 R120 (475') (379'-476'), Hinge 1-15 (477'-491'), Ch2 L1.3>A (495'), L1.2>A (496') (492'-601'), Ch3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), Chs K2>Del (707')) (379'-707')]]; Dimer (485-487':488-490')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform AlfaBoehringer IngelheimP3BB

+42 more in the Small Cell Lung Carcinoma cohort

Other indications for bl0020

IndicationSponsorPhaseRating
Cancer—P1C · 36

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. bl0020 in Small Cell Lung Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/bl0020-small-cell-lung-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →